Enzyme kinetics from circular dichroism of insulin reveals mechanistic insights into the regulation of insulin-degrading enzyme

被引:10
作者
Ivancic, Valerie A. [1 ]
Krasinski, Claire A. [1 ]
Zheng, Qiuchen [1 ]
Meservier, Rebecca J. [1 ]
Spratt, Donald E. [1 ]
Lazo, Noel D. [1 ]
机构
[1] Clark Univ, Carlson Sch Chem & Biochem, 950 Main St, Worcester, MA 01610 USA
基金
美国国家卫生研究院;
关键词
AMYLOID BETA-PROTEIN; TYPE-2; DIABETES-MELLITUS; ALZHEIMERS-DISEASE; FIBRIL FORMATION; IN-VIVO; ATP; RECOGNITION; BINDING; INHIBITION; ACTIVATION;
D O I
10.1042/BSR20181416
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Insulin-degrading enzyme (IDE) is a zinc metalloprotease that selectively degrades biologically important substrates associated with type 2 diabetes and Alzheimer's disease (AD). As such, IDE is an attractive target for therapeutic innovations. A major requirement is an understanding of how other molecules present in cells regulate the activity of the enzyme toward insulin, IDE's most important physiologically relevant substrate. Previous kinetic studies of the IDE-dependent degradation of insulin in the presence of potential regulators have used iodinated insulin, a chemical modification that has been shown to alter the biological and biochemical properties of insulin. Here, we present a novel kinetic assay that takes advantage of the loss of helical circular dichroic signals of insulin with IDE-dependent degradation. As proof of concept, the resulting Michaelis-Menten kinetic constants accurately predict the known regulation of IDE by adenosine triphosphate (ATP). Intriguingly, we found that when Mg2+ is present with ATP, the regulation is abolished. The implication of this result for the development of preventative and therapeutic strategies for AD is discussed. We anticipate that the new assay presented here will lead to the identification of other small molecules that regulate the activity of IDE toward insulin.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Insulin-degrading enzyme, apolipoprotein E, and Alzheimer’s disease
    Steven D. Edland
    Journal of Molecular Neuroscience, 2004, 23 : 213 - 217
  • [42] Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease
    Edland, SD
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2004, 23 (03) : 213 - 217
  • [43] Insulin-degrading enzyme is activated by the C-terminus of α-synuclein
    Sharma, Sandeep K.
    Chorell, Erik
    Wittung-Stafshede, Pernilla
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 466 (02) : 192 - 195
  • [44] Developmental regulation of insulin-degrading enzyme in long-term hippocampal cell culture
    Du, Jing
    Qu, Yi-bo
    Wang, Zhao
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 103 - 103
  • [45] Optimization of Peptide Hydroxamate Inhibitors of Insulin-Degrading Enzyme Reveals Marked Substrate-Selectivity
    Abdul-Hay, Samer O.
    Lane, Amy L.
    Caulfield, Thomas R.
    Claussin, Clemence
    Bertrand, Juliette
    Masson, Amandine
    Choudhry, Shakeel
    Fauq, Abdul H.
    Maharvi, Guhlam M.
    Leissring, Malcolm A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (06) : 2246 - 2255
  • [46] Glucose inhibits the insulin-induced activation of the insulin-degrading enzyme in HepG2 cells
    Pivovarova, O.
    Goegebakan, Oe
    Pfeiffer, A. F. H.
    Rudovich, N.
    DIABETOLOGIA, 2009, 52 (08) : 1656 - 1664
  • [47] Reduced Insulin Clearance and Insulin-Degrading Enzyme Activity Contribute to Hyperinsulinemia in African Americans
    Fosam, Andin
    Sikder, Shanaz
    Abel, Brent S.
    Tella, Sri Harsha
    Walter, Mary F.
    Mari, Andrea
    Muniyappa, Ranganath
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (04) : E1835 - E1846
  • [48] From virus to diabetes therapy: Characterization of a specific insulin-degrading enzyme inhibitor for diabetes treatment
    Nash, Yuval
    Ganoth, Assaf
    Borenstein-Auerbach, Nofit
    Levy-Barazany, Hilit
    Goldsmith, Guy
    Kopelevich, Adi
    Pozyuchenko, Katia
    Sakhneny, Lina
    Lazdon, Ekaterina
    Blanga-Kanfi, Shani
    Alhadeff, Raphael
    Benromano, Tali
    Landsman, Limor
    Tsfadia, Yossi
    Frenkel, Dan
    FASEB JOURNAL, 2021, 35 (05)
  • [49] Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?
    Pivovarova, Olga
    Hoehn, Annika
    Grune, Tilman
    Pfeiffer, Andreas F. H.
    Rudovich, Natalia
    ANNALS OF MEDICINE, 2016, 48 (08) : 614 - 624
  • [50] Metabolism of Cryptic Peptides Derived from Neuropeptide FF Precursors: The Involvement of Insulin-Degrading Enzyme
    Grasso, Giuseppe
    Mielczarek, Przemyslaw
    Niedziolka, Magdalena
    Silberring, Jerzy
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (09): : 16787 - 16799